BidaskClub upgraded shares of Illumina (NASDAQ:ILMN) from a hold rating to a buy rating in a report published on Saturday morning.
ILMN has been the subject of a number of other research reports. BTIG Research reiterated a hold rating on shares of Illumina in a research report on Tuesday, January 16th. Wells Fargo & Co upgraded Illumina from a market perform rating to an outperform rating and set a $205.00 price target for the company in a research report on Tuesday, January 2nd. Evercore ISI assumed coverage on Illumina in a research report on Wednesday, January 3rd. They set an outperform rating and a $250.00 price target for the company. Zacks Investment Research upgraded Illumina from a hold rating to a buy rating and set a $252.00 price target for the company in a research report on Tuesday, December 5th. Finally, Canaccord Genuity reiterated a buy rating and set a $265.00 price target (up previously from $255.00) on shares of Illumina in a research report on Wednesday, January 31st. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and fifteen have issued a buy rating to the stock. Illumina presently has an average rating of Buy and an average target price of $241.39.
Shares of Illumina (ILMN) opened at $253.54 on Friday. The stock has a market capitalization of $37,270.00, a PE ratio of 42.68, a PEG ratio of 3.31 and a beta of 0.93. The company has a current ratio of 3.99, a quick ratio of 3.55 and a debt-to-equity ratio of 0.43. Illumina has a 12-month low of $158.02 and a 12-month high of $256.05.
In other Illumina news, Director Jay T. Flatley sold 20,000 shares of Illumina stock in a transaction that occurred on Tuesday, December 19th. The stock was sold at an average price of $215.48, for a total value of $4,309,600.00. Following the transaction, the director now directly owns 480,476 shares of the company’s stock, valued at approximately $103,532,968.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Robert S. Epstein sold 1,250 shares of Illumina stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $244.18, for a total value of $305,225.00. Following the completion of the transaction, the director now directly owns 8,588 shares in the company, valued at $2,097,017.84. The disclosure for this sale can be found here. Insiders sold a total of 72,887 shares of company stock worth $16,510,025 over the last ninety days. Insiders own 0.89% of the company’s stock.
A number of institutional investors have recently made changes to their positions in the business. Hemenway Trust Co LLC increased its stake in Illumina by 0.6% in the 4th quarter. Hemenway Trust Co LLC now owns 37,895 shares of the life sciences company’s stock worth $8,280,000 after purchasing an additional 227 shares during the period. Daiwa Securities Group Inc. increased its stake in Illumina by 4.3% in the 4th quarter. Daiwa Securities Group Inc. now owns 5,543 shares of the life sciences company’s stock worth $1,211,000 after purchasing an additional 229 shares during the period. Private Asset Management Inc. increased its stake in Illumina by 2.2% in the 4th quarter. Private Asset Management Inc. now owns 11,072 shares of the life sciences company’s stock worth $2,419,000 after purchasing an additional 240 shares during the period. Fairfield Bush & CO. increased its stake in Illumina by 1.4% in the 4th quarter. Fairfield Bush & CO. now owns 18,985 shares of the life sciences company’s stock worth $4,148,000 after purchasing an additional 255 shares during the period. Finally, Nordea Investment Management AB increased its stake in Illumina by 4.1% in the 3rd quarter. Nordea Investment Management AB now owns 7,076 shares of the life sciences company’s stock worth $1,410,000 after purchasing an additional 278 shares during the period. 91.51% of the stock is currently owned by institutional investors and hedge funds.
WARNING: “Illumina (ILMN) Stock Rating Upgraded by BidaskClub” was published by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this piece of content on another site, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://sportsperspectives.com/2018/03/14/illumina-ilmn-stock-rating-upgraded-by-bidaskclub.html.
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.